22nd Century Announces $35 Million Registered Direct Offering Priced Above Market under Nasdaq Rules
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), leading agricultural…
Year: 2022
Better Choice Company to Host Second Quarter 2022 Earnings Call on August 11th at 8:30 a.m. ET
NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice”…
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing…
Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022
STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics (NASDAQ: PLRX) announced…
Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference
FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”)…
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-Clinical Development Erin O’Neil, M.D., appointed Vice…
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect…
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage…
BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage…
iSpecimen to Report Second Quarter 2022 Results on August 4, 2022
LEXINGTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Adamis Pharmaceuticals Issues Letter to Stockholders
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
BioCryst to Report Second Quarter 2022 Financial Results on August 4
RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint….
IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell…
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta…
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022…